for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Mereo BioPharma Group PLC

MREO.OQ

Latest Trade

2.80USD

Change

0.03(+1.08%)

Volume

214

Today's Range

2.80

 - 

2.80

52 Week Range

0.69

 - 

4.25

As of on the London Stock Exchange (LON) ∙ Minimum 15 minute delay

Pricing

Previous Close
2.77
Open
2.80
Volume
214
3M AVG Volume
18.32
Today's High
2.80
Today's Low
2.80
52 Week High
4.25
52 Week Low
0.69
Shares Out (MIL)
338.71
Market Cap (MIL)
143.95
Forward P/E
--
Dividend (Yield %)
--

Next Event

Mereo BioPharma Group plc Annual Shareholders Meeting

Latest Developments

More

Mereo Biopharma Group Files For Offering Of Up To 103.1 Million Adss By The Selling Shareholders

Mereo Biopharma Group FY Loss After Tax £35.3 Mln

Mereo BioPharma Announces Completion Of $70 Mln Private Placement

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Mereo BioPharma Group PLC

Mereo BioPharma Group PLC is a United Kingdom-based biopharmaceutical company. The Company is focused on development and commercialization of therapeutics for patients with rare diseases. Its pipeline includes BPS-804, MPH-966, BCT-197, BGS-649, Navicixizumab and Etigilimab. BPS-804 (setrusumab) is being developed to improve bone strength and thereby reduce fractures in the orphan disease osteogenesis imperfecta (OI). MPH-966 (alvelestat) is being developed for alpha-1 antitrypsin deficiency (AATD). BGS-649 (leflutrozole) is being developed for the treatment of obese men with hypogonadotropic hypogonadism (HH). BCT-197 (acumapimod) is being developed as a therapy for acute exacerbations of chronic obstructive pulmonary disease (AECOPD). Navicixizumab is being developed for platinum-resistant ovarian cancer. Etigilimab is being developed for advanced or metastatic solid tumors.

Industry

Biotechnology & Drugs

Contact Info

Fourth Fl, 1 Cavendish Place

W1G 0QF

United Kingdom

http://www.mereobiopharma.com/

Executive Leadership

Peter J. Fellner

Independent Non-Executive Chairman of the Board

Denise V. Scots-Knight

Chief Executive Officer, Co-Founder, Executive Director

Charles E. Sermon

Co-Founder, General Counsel, Company Secretary

Alastair G. MacKinnon

Chief Medical Officer and Co-Founder

John P. Richard

Head of Corporate Development and Co-Founder

Key Stats

2.00 mean rating - 1 analysts
Sell
Hold
Buy
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
1.03
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
80.52
LT Debt To Equity (MRQ)
36.49
Return on Investment (TTM)
-64.72
Return on Equity (TTM)
-45.33

Latest News

Latest News

BRIEF-Mereo Biopharma Group Files For Offering Of Up To 103.1 Million Adss By The Selling Shareholders

* MEREO BIOPHARMA GROUP PLC FILES FOR OFFERING OF UP TO 103.1 MILLION ADSS BY THE SELLING SHAREHOLDERS - SEC FILING Source text: [https://bit.ly/2DgLAcc] Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Mereo Biopharma Group FY Loss After Tax £35.3 Mln

* MEREO BIOPHARMA GROUP PLC - LOSS AFTER TAX FOR 12-MONTH PERIOD OF £35.3 MILLION (2018: £32.0 MILLION)

BRIEF-Mereo Biopharma Reports Completion Of $70 Mln Private Placement

* MEREO BIOPHARMA ANNOUNCES COMPLETION OF $70 MILLION PRIVATE PLACEMENT Source text for Eikon: Further company coverage:

BRIEF-Mereo BioPharma Announces Completion Of $70 Mln Private Placement

* COMPLETION OF A $70 MILLION (£56 MILLION) PRIVATE PLACEMENT WITH NEW & EXISTING U.S BASED INSTITUTIONAL & ACCREDITED INVESTORS

BRIEF-Mereo Biopharma Announces Positive Feedback From Phase 2 Meeting With FDA

* MEREO BIOPHARMA GRP - POSITIVE FEEDBACK FROM PHASE 2 MEETING WITH FDA

BRIEF-Mereo Biopharma Says Have A Clear Path Forward To Initiate Late-Stage Study Of Setrusumab

* MEREO BIOPHARMA ANNOUNCES POSITIVE FEEDBACK FROM TYPE B END-OF-PHASE 2 MEETING WITH THE FDA AND OUTLINES PIVOTAL PHASE 3 PEDIATRIC STUDY DESIGN FOR SETRUSUMAB IN OSTEOGENESIS IMPERFECTA

BRIEF-Mereo Biopharma Enters Into Securities Purchase Agreement With An Institutional Healthcare Investor

* MEREO BIOPHARMA GROUP PLC - HAS ENTERED INTO A SECURITIES PURCHASE AGREEMENT WITH A NEW U.S.-BASED INSTITUTIONAL HEALTHCARE INVESTOR

BRIEF-Mereo Biopharma Group Files Prospectus Relates To Sale Of Up To $28.3 Mln Or 17.9 Mln Adss By Aspire Capital Fund

* MEREO BIOPHARMA GROUP PLC FILES PROSPECTUS RELATES TO SALE OF UP TO $28.3 MILLION OR 17.9 MILLION ADSS BY ASPIRE CAPITAL FUND, LLC - SEC FILING Source text: (https://bit.ly/2uNh7ic) Further company coverage:

BRIEF-Mereo Biopharma Updates On Cash Distribution

* MEREO BIOPHARMA - DISTRIBUTING ABOUT 1.2 CENTS CASH/CONTINGENT VALUE RIGHT ON $4 MILLION UPFRONT MILESTONE PAYMENT FROM LICENSE AGREEMENT WITH ONCOLOGIE Source text for Eikon: Further company coverage:

BRIEF-Mereo Biopharma Enters Into $5 Mln Equity Financing With Novartis

* MEREO BIOPHARMA GROUP PLC - MEREO BIOPHARMA ENTERS INTO A $5 MILLION CONVERTIBLE EQUITY FINANCING WITH NOVARTIS

BRIEF-Mereo Biopharma Group PLC Files For U.S. IPO Of Up To $80.5 Million

* MEREO BIOPHARMA GROUP PLC FILES FOR U.S. IPO OF UP TO $80.5 MILLION – SEC FILING

BRIEF-Mereo plans U.S. IPO in first half 2018

* PROPOSED OFFERING IS EXPECTED TO COMMENCE IN FIRST HALF OF 2018 Source text for Eikon: Further company coverage:

BRIEF-Mereo Biopharma signs agreement with AstraZeneca

* DEAL FOR AN EXCLUSIVE LICENSE AND OPTION TO ACQUIRE AZD9668

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up